Advertisement

Topics

Newron Pharmaceuticals SpA Company Profile

04:14 EST 16th December 2018 | BioPortfolio

Newron Pharmaceuticals SpA is a clinical stage biopharmaceutical company focused on the discovery and development of small molecule drugs for the treatment of central nervous system (CNS) diseases. Our clinical focus is on Parkinson's disease and pain. We were established in 1999 as a spin-off from Pharmacia & Upjohn and are headquartered in Bresso, near Milan, Italy. We are conducting Phase III clinical trials with safinamide, a molecule with multiple mechanisms of action for the treatment of Parkinson’s disease and Phase II trials for Restless Leg Syndrome. Phase II clinical trials with ralfinamide, an innovative treatment for neuropathic pain, are on-going. Newron’s clinical pipeline is supported by a broad portfolio of early stage proprietary compounds generated by our ion channel drug discovery platform or in-licensed. We maintain a broad portfolio of discovery and development programs which enables to diversify risk and utilize our development capacity fully.

Location

via Ludovico Ariosto 21
Bresso
Milano
20091
Italy

Contact

Phone: 39 02 610 3461
Fax: 39 02 610 34654
Email: info@ newron.com


News Articles [322 Associated News Articles listed on BioPortfolio]

Newron Pharmaceuticals to Host 2018 R&D Day on October 31 in New York City - Save the Date

Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous sys...

DGAP-News: Newron Pharmaceuticals S.p.A.: EU-Investitionsoffensive - EIB unterstützt italienischen Entwickler von ZNS-Therapeutika Newron Pharmaceuticals mit bis zu EUR 40 Mio. (deutsch)

Newron Pharmaceuticals S.p.A.: EU-Investitionsoffensive - EIB unterstützt italienischen Entwickler von ZNS-Therapeutika Newron Pharmaceuticals mit bis zu EUR 40 Mio. DGAP-News: Newron Pharmaceutica.....

Newron Pharmaceuticals (NWRN) - Next up - R&D day

Edison Investment Research - Pharmaceutical & healthcare - Newron Pharmaceuticals: Newron continued to made steady progress in H118. A fuller debrief of pipeline assets including sarizotan (Rett syndr...

Newron Pharmaceuticals (NWRN) - Next up, R&D day

Edison Investment Research - Pharmaceutical & healthcare - Newron Pharmaceuticals: Newron continued to make steady progress in H118. A fuller debrief of pipeline assets including sarizotan (Rett syndr...

Newron Pharmaceuticals to Present at H.C. Wainwright Annual Healthcare Conference

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the c...

Newron Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference in New York

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the c...

Newron Pharmaceuticals: Xadago-Lizenzeinnahmen in H1 unter Erwartungen

Zürich (www.aktiencheck.de) - Newron Pharmaceuticals-Aktienanalyse von Aktienanalyst Stefan Schneider von Vontobel Research: Stefan Schneider, Aktienanalyst von Vontobel Research, bestätigt in eine....

Newron Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the centr...

Drugs and Medications [270 Associated Drugs and Medications listed on BioPortfolio]

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash

Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash

Antacid [Major Pharmaceuticals]

Major Pharmaceuticals Antacid Tablets Drug Facts

Eyewash station additive concentrate [Niagara Pharmaceuticals Inc.]

EYEWASH STATION ADDITIVE CONCENTRATE

PubMed Articles [128 Associated PubMed Articles listed on BioPortfolio]

Swimming activity in zebrafish larvae exposed to veterinary antiparasitic pharmaceuticals.

Veterinary antiparasitic pharmaceuticals have been detected in surface waters and several of these pharmaceuticals act on the nervous system on the target organisms implying that neurological effects ...

Chiral pharmaceuticals: Environment sources, potential human health impacts, remediation technologies and future perspective.

Chiral pharmaceuticals (CPs), including non-steroid anti-inflammatory drugs (NSAIDs), β-blockers and some herbicide and pesticides, are widely used in aquaculture, clinical treatment and many other f...

Assessment of 83 pharmaceuticals in WWTP influent and effluent samples by UHPLC-MS/MS: Hourly variation.

The removal efficiency of pharmaceuticals in wastewater treatment plants (WWTPs) is variable and some of these compounds pass these plants almost intact and others presenting a removal efficiency clos...

Effects of pharmaceuticals on microbial communities and activity of soil enzymes in mesocosm-scale constructed wetlands.

Cyperus alternifolius based mesocosm-scale constructed wetland was employed to remove pharmaceuticals. We investigated the microbial community composition using phosphor lipid fatty acids (PFLAs) anal...

Impact of Pharmaceuticals on the Environment: Risk Assessment Using QSAR Modeling Approach.

An extensive use of pharmaceuticals and the widespread practices of their erroneous disposal measures have made these products contaminants of emerging concern (CEC). Especially, active pharmaceutical...

Clinical Trials [228 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Companies [1341 Associated Companies listed on BioPortfolio]

Newron Pharmaceuticals S.p.A.

Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain. The Compan...

Newron Pharmaceuticals SpA

Newron Pharmaceuticals SpA is a clinical stage biopharmaceutical company focused on the discovery and development of small molecule drugs for the treatment of central nervous system (CNS) diseases. Ou...

Maelor Pharmaceuticals Ltd.

Maelor is a publicly listed (AIM:MLR) specialist critical care pharmaceuticals and devices company. The Company has developed an expertise in bringing both pharmaceuticals and devices to the market as...

Excaliard Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...

Serenity Pharmaceuticals

Founded in 2007 and located in Milford, Pennsylvania, Serenity Pharmaceuticals is focused on developing products that address urinary conditions that impact the health and well-be...

More Information about "Newron Pharmaceuticals SpA" on BioPortfolio

We have published hundreds of Newron Pharmaceuticals SpA news stories on BioPortfolio along with dozens of Newron Pharmaceuticals SpA Clinical Trials and PubMed Articles about Newron Pharmaceuticals SpA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Newron Pharmaceuticals SpA Companies in our database. You can also find out about relevant Newron Pharmaceuticals SpA Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...


Corporate Database Quicklinks



Searches Linking to this Company Record